Is Lapatinib included in medical insurance?

The original drug Lapatinib (Lapatinib) has been marketed in China, but it has not yet been included in the medical insurance through the relevant policies of the National Medical Insurance Administration. Patients can only purchase this drug at their own expense. The price of each box of 0.25g*70 tablets may be more than 5,000 yuan. For specific prices, please consult the local hospital pharmacy. Lapatinib is an oral anti-cancer drug that belongs to a class of targeted therapy drugs. It was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for the treatment of breast cancer and is typically used to treat a specific type of breast cancer, HER2-positive breast cancer. The mechanism of action of lapatinib is to reduce the growth and division of cancer cells by inhibiting the activation of two receptors, HER2 and EGFR (epidermal growth factor receptor).